EN DE
Watch ORGANOIDSCIENCES for free: we tell you when fair value or trend changes.
Data-driven stock valuation

ORGANOIDSCIENCES (476040) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of ORGANOIDSCIENCES stock KRW 3,951, price KRW 4,500, that is 12.2% below the price, quality 38 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

O ORGANOIDSCIENCES logo Thin data Nov 16, 2026

ORGANOIDSCIENCES

476040 · KQ

Expensive (fair value 12% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Expensive Growth (revenue 3y +76.4 %/yr in KRW) 
Fair value 3,951 KRW · Overvalued 
Quality 38/100 
Falling price (downtrend) 
Negative free cash flow 
Trails peers (2/8) 
Narrow moat 8/100 · thin data
Thin data 
Estimate
Watch ORGANOIDSCIENCES for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

48,150 KRW 4,500 KRW Fair Value 3,951 KRW May 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

18‑month range 4,500 KRW – 48,150 KRW · fair‑value band 2,963 KRW – 4,938 KRW · the 4,500 KRW price screens above the 3,951 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow ORGANOIDSCIENCES in your weekly email

Every Wednesday you see whether ORGANOIDSCIENCES is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Organoidsciences Ltd. develops regenerative therapies in South Korea.

Show moreShow less

It develops ATORM, an adult tissue derived organoid based regenerative medicine platform for the treatment of intractable intestinal ulcers, as well as salivary glands, liver, and uterus disease areas; ODISEI solutions, an organoid-based discovery platform for screening evaluation and identification; and EXPANSION, an organoid-based advanced science for innovative solutions.

The company was founded in 2018 and is based in Seongnam-si, South Korea.

Stock analysis

ORGANOIDSCIENCES (476040) currently trades at 4,500 KRW, while our estimate is 3,951 KRW, 12% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 2,963 KRW (bear) to 4,938 KRW (bull), the price of 4,500 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

ORGANOIDSCIENCES reported revenue of 2.4B KRW in FY2025 versus 270M KRW in FY2021, a compound +72.7%/yr. Reported net income was −15.4B KRW in FY2025.

Key figures

Market cap 29.6B KRW (≈ $22.1M) Micro · P/S ratio 15.7 · EPS (TTM) −2,802 KRW · Return on equity −62.3% · Return on assets (EBIT) −32.0% (5-year average) · Operating margin −728% · Revenue (TTM) 2.3B KRW · Revenue growth (YoY) −1.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 90% below its 52-week high and at its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −12%, 476040 screens richer than that median.

Fair Value

Bear 2,963 KRW Fair Value 3,951 KRW Bull 4,938 KRW
Price 4,500 KRW · Downside -12.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 38/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 2
How much profit the company makes from its sales and capital
Quality Growth 52
Are margins and returns getting better?
Cashflow 9
Do the profits arrive as real cash?
Financial strength 59
Debt, balance sheet and risk of trouble
Investment 50
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 77
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+23.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+76.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,743.7% (2021) → −673.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

476040 screens overvalued: fair value 12% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare ORGANOIDSCIENCES with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 38 · Below median
Fair Value upside −16.1% · Above median
Profitability
Return on assets −41.3% · Below median
Growth and dividend
Revenue growth (quarter YoY) −1.1% · Below median
Balance sheet
Debt / equity 0.09× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.26× · Cheapest 25%
P/S (12 months) 13.53× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)12 · sector 0
FUTURE (revenue growth)0 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)96 · sector 96
DIVIDEND (yield)0 · sector 21

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs 476040
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs 476040
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs 476040
argenx SE ARGX $950.95 $908.40 −4% vs 476040
CSL Limited CSL A$199.55 A$186.49 −7% vs 476040
Moderna, Inc MRNA $215.27 $135.64 −37% vs 476040
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs 476040
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs 476040
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs 476040
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs 476040

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ORGANOIDSCIENCES: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "ORGANOIDSCIENCES Fair Value". https://www.fairvalue-calculator.com/stock/476040

Frequently asked questions

Is ORGANOIDSCIENCES (476040) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is 3,951 KRW versus a price of 4,500 KRW, about 12% lower (overvalued).
What is the fair value of 476040?
Our estimate for ORGANOIDSCIENCES is 3,951 KRW (as of Nov 16, 2026), built from audited fundamentals. The current price: 4,500 KRW.
What is the quality score of 476040?
ORGANOIDSCIENCES has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ORGANOIDSCIENCES (476040)?
Our calculated price target is the estimate of 3,951 KRW (as of Nov 16, 2026). Cautious scenario 2,963 KRW, optimistic scenario 4,938 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the ORGANOIDSCIENCES stock forecast for 2026?
Our estimate puts fair value at 3,951 KRW, about 12% lower versus a price of 4,500 KRW (overvalued). Cautious scenario 2,963 KRW, optimistic scenario 4,938 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of ORGANOIDSCIENCES (476040)?
ORGANOIDSCIENCES reported trailing-twelve-month revenue of about 2.3B KRW (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of ORGANOIDSCIENCES (476040)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ORGANOIDSCIENCES it is 3,951 KRW per share (as of Nov 16, 2026), against a price of 4,500 KRW.
Is ORGANOIDSCIENCES stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 476040 trades above its calculated fair value: price 4,500 KRW, fair value 3,951 KRW, a gap of about −12% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 476040?
No. The price is what the market pays today (4,500 KRW); the fair value is what the company's own numbers justify (3,951 KRW). For ORGANOIDSCIENCES the two are 549.47 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is ORGANOIDSCIENCES worth?
The market values ORGANOIDSCIENCES at about 29.6B KRW (market capitalisation, as of Nov 16, 2026). Per share that is 4,500 KRW; our models calculate a fair value of 3,951 KRW per share.
What do the bullish and bearish scenarios say about 476040?
Our models span a range for ORGANOIDSCIENCES: cautious scenario 2,963 KRW, base 3,951 KRW, optimistic 4,938 KRW per share (as of Nov 16, 2026, price 4,500 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ORGANOIDSCIENCES (476040)?
Balance-sheet figures for ORGANOIDSCIENCES (as of Nov 16, 2026): return on equity −62.3%, debt of 0.09 per unit of equity. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is 476040 from its 52-week high?
ORGANOIDSCIENCES trades at 4,500 KRW, about 90% below its 52-week high of 44,600 KRW and at the low of 4,500 KRW (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of 3,951 KRW is for.
Which stocks are comparable to ORGANOIDSCIENCES?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ORGANOIDSCIENCES stock attractive at the current price?
The data as of Nov 16, 2026: price 4,500 KRW, calculated fair value 3,951 KRW (−12%), Quality Score 38/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. ORGANOIDSCIENCES itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ORGANOIDSCIENCES (476040)?
The closing price on Nov 17, 2026 was 4,500 KRW. Our estimate is 3,951 KRW, about 12% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ORGANOIDSCIENCES right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of ORGANOIDSCIENCES

How large is the market capitalisation of ORGANOIDSCIENCES (476040)?
The market capitalisation of ORGANOIDSCIENCES is 29.6B KRW (≈ $22.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ORGANOIDSCIENCES (476040)?
The price-to-sales ratio of ORGANOIDSCIENCES is 15.7 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of ORGANOIDSCIENCES (476040)?
Earnings per share at ORGANOIDSCIENCES are −2,802 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of ORGANOIDSCIENCES (476040)?
The return on equity (ROE) of ORGANOIDSCIENCES is −62.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ORGANOIDSCIENCES (476040)?
On an EBIT basis the return on assets of ORGANOIDSCIENCES is −32.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ORGANOIDSCIENCES (476040)?
The operating margin of ORGANOIDSCIENCES is −728% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ORGANOIDSCIENCES (476040)?
Revenue at ORGANOIDSCIENCES is down 1.1% versus a year earlier (3y avg +76.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does ORGANOIDSCIENCES (476040) generate?
The free cash flow of ORGANOIDSCIENCES is −16.0B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does ORGANOIDSCIENCES (476040) carry?
The net debt of ORGANOIDSCIENCES is 295M KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch ORGANOIDSCIENCES in the live analysis

One click puts ORGANOIDSCIENCES on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.